

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Transcept Pharmaceuticals, Inc.		12/07/2011	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Purdue Pharmaceutical Products L.P.		
Composed Of:	COMPOSED OF Purdue Pharmaceutical Products Inc., a New York Corporation, as General Partner		
Street Address:	One Stamford Forum		
City:	Stamford		
State/Country:	CONNECTICUT		
Postal Code:	06901		
Entity Type:	LIMITED PARTNERSHIP: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	3327586	INTERMID	
Registration Number:	3327585	INTERMEZZO	
CORRESPONDENCE DATA			
Fax Number:	(203)588-6204		
Phone:	203-588-8390		
Email:	peter.mendelson@pharma.com		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Correspondent Name:	Peter Mendelson		
Address Line 1:	One Stamford Forum		
Address Line 4:	Stamford, CONNECTICUT 06901		
NAME OF SUBMITTER:	Peter Mendelson		
Signature:	/Peter Mendelson/		

Date:

01/03/2012

Total Attachments: 2


source=Intermezzo Trademark Assignment (United States) dated 12-7-11#page1.tif

source=Intermezzo Trademark Assignment (United States) dated 12-7-11#page2.tif

Trademark Assignment (United States)

TRANSCCEPT PHARMACEUTICALS, INC., a Delaware corporation having its principal offices at 1003 W. Cutting Blvd, Suite #110, Pt. Richmond, California 94804 ("Transcept"), owning the entire ownership of each of the INTERMEZZO™ and INTERMID™ trademarks set forth on Schedule A hereto, hereby, for good and valuable consideration received by Transcept, (a) confirms that it has sold and assigned, and does hereby sell and assign, to PURDUE PHARMACEUTICAL PRODUCTS L.P., a Delaware limited partnership having a place of business at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901-3431 ("Purdue"), its successors and assigns the entire ownership interest in each of the INTERMEZZO™ and INTERMID™ trademarks set forth on Schedule A hereto and the goodwill attached thereto, to be held and enjoyed by Purdue, its successors, assigns or other legal representatives, to the full end of the term thereof, as may be extended by law as fully and entirely as the same would have been held and enjoyed by Transcept if this assignment and sale had not been made, including, but not limited to, the right to sue for past infringement, and (b) authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority to issue any trademark, and any extensions or Supplementary Protections, resulting from or based in whole upon said INTERMEZZO™ and INTERMID™ trademarks to Purdue.

Transcept Pharmaceuticals, Inc.

By: 
Name: Glenn A. Oclassen
Title: President and Chief Executive Officer

Dated: December 7, 2011

Schedule A

Trademark	Registration #	Registration Date	Country Name
INTERMID	3327586	30-Oct-2007	United States of America
INTERMEZZO	3327585	30-Oct-2007	United States of America